COVID-19 and inflammatory bowel disease: A pathophysiological assessment
Open Access
- 1 March 2021
- journal article
- review article
- Published by Elsevier BV in Biomedicine & Pharmacotherapy
- Vol. 135, 111233
- https://doi.org/10.1016/j.biopha.2021.111233
Abstract
No abstract availableFunding Information
- Zhongnan Hospital of Wuhan University
- Wuhan University
This publication has 52 references indexed in Scilit:
- Understanding cytokine release syndromeIntensive Care Medicine, 2017
- Crohn's diseaseThe Lancet, 2016
- PARP inhibition protective against alcoholic steatohepatitis and NASHNature Reviews Gastroenterology & Hepatology, 2016
- Immunopathogenesis of IBD: current state of the artNature Reviews Gastroenterology & Hepatology, 2015
- Review article: cytomegalovirus and inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2015
- Coronaviruses: An Overview of Their Replication and PathogenesisPublished by Springer Science and Business Media LLC ,2015
- Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitorsAmino Acids, 2014
- ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammationNature, 2012
- The role of the neutral amino acid transporter B0AT1 (SLC6A19) in Hartnup disorder and protein nutritionIUBMB Life, 2009
- A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumabJournal of Dermatological Treatment, 2004